WITHDRAWN: Ten-year follow-up of patients with refractory systemic juvenile idiopathic arthritis after the clinical trial of tocilizumab as a first biologic disease-modifying antirheumatic drug.

Miyamae T, Nishimura K, Imagawa T, Inoue E, Hattori S, Ishii T, Ito S, Iwata N, Kamata Y, Kamiyama Y, Kaneko U, Mizuta M, Mori M, Murase A, Nakagishi Y, Nakano N, Nakano T, Nakayamada S, Naniwa T, Nozawa T, Ohya T, Okamoto N, Sato K, Sugita Y, Takei S, Tanaka S, Tanaka Y, Tomiita M, Umebayashi H, Yamasaki Y, Nishimoto N, Yokota S

Open source

DOI: 10.1016/j.ero.2025.06.007
Published: 2026 Jun
Container: EULAR rheumatology open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ero.2025.06.007,
  title = {WITHDRAWN: Ten-year follow-up of patients with refractory systemic juvenile idiopathic arthritis after the clinical trial of tocilizumab as a first biologic disease-modifying antirheumatic drug.},
  author = {Miyamae T and Nishimura K and Imagawa T and Inoue E and Hattori S and Ishii T and Ito S and Iwata N and Kamata Y and Kamiyama Y and Kaneko U and Mizuta M and Mori M and Murase A and Nakagishi Y and Nakano N and Nakano T and Nakayamada S and Naniwa T and Nozawa T and Ohya T and Okamoto N and Sato K and Sugita Y and Takei S and Tanaka S and Tanaka Y and Tomiita M and Umebayashi H and Yamasaki Y and Nishimoto N and Yokota S},
  year = {2026},
  journal = {EULAR rheumatology open},
  doi = {10.1016/j.ero.2025.06.007},
  url = {https://doi.org/10.1016/j.ero.2025.06.007}
}

RIS

TY  - JOUR
TI  - WITHDRAWN: Ten-year follow-up of patients with refractory systemic juvenile idiopathic arthritis after the clinical trial of tocilizumab as a first biologic disease-modifying antirheumatic drug.
AU  - Miyamae T
AU  - Nishimura K
AU  - Imagawa T
AU  - Inoue E
AU  - Hattori S
AU  - Ishii T
AU  - Ito S
AU  - Iwata N
AU  - Kamata Y
AU  - Kamiyama Y
AU  - Kaneko U
AU  - Mizuta M
AU  - Mori M
AU  - Murase A
AU  - Nakagishi Y
AU  - Nakano N
AU  - Nakano T
AU  - Nakayamada S
AU  - Naniwa T
AU  - Nozawa T
AU  - Ohya T
AU  - Okamoto N
AU  - Sato K
AU  - Sugita Y
AU  - Takei S
AU  - Tanaka S
AU  - Tanaka Y
AU  - Tomiita M
AU  - Umebayashi H
AU  - Yamasaki Y
AU  - Nishimoto N
AU  - Yokota S
PY  - 2026
JO  - EULAR rheumatology open
DO  - 10.1016/j.ero.2025.06.007
UR  - https://doi.org/10.1016/j.ero.2025.06.007
ER  -

APA

T, M., K, N., T, I., E, I., S, H., T, I., S, I., N, I., Y, K., Y, K., U, K., M, M., M, M., A, M., Y, N., N, N., T, N., S, N., T, N., T, N., T, O., N, O., K, S., Y, S., S, T., S, T., Y, T., M, T., H, U., Y, Y., N, N., & S, Y. (2026). WITHDRAWN: Ten-year follow-up of patients with refractory systemic juvenile idiopathic arthritis after the clinical trial of tocilizumab as a first biologic disease-modifying antirheumatic drug.. EULAR rheumatology open. https://doi.org/10.1016/j.ero.2025.06.007

Source records

pubmed · retrieved 2026-09-25T06:45:55.840Z